News & Publications

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

  • 27

    Sep

    21

  • KemPharm to Present at the Benzinga Healthcare Small Cap Conference

  • 23

    Sep

    21

  • KemPharm to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference

  • 09

    Sep

    21

  • KemPharm to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference

  • 18

    Aug

    21

  • KemPharm Appoints Tamara A. Seymour to Board of Directors

  • 12

    Aug

    21

  • KemPharm Reports Second Quarter 2021 Financial Results

  • 05

    Aug

    21

  • KemPharm to Report Second Quarter 2021 Results

  • 21

    Jul

    21

  • KemPharm Announces U.S. Launch of Innovative ADHD Treatment AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules) by Corium, Inc.

  • 18

    Jun

    21

  • KemPharm Announces Exercise of Existing Warrants and Issuance of Warrants in Private Placement

  • 16

    Jun

    21

  • KemPharm Issues Letter to Shareholders

  • 09

    Jun

    21

  • KemPharm to be Added to Russell 2000® and Russell 3000® Indexes Effective June 28, 2021

  • 03

    Jun

    21

  • KemPharm Executives to Participate in Panel Discussions During Upcoming June 2021 Conferences

  • 26

    May

    21

  • KemPharm, Inc. Announces Orange Book Listing for Six Patents Covering Serdexmethylphenidate (SDX) and Confirmation of NCE Status